Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-BOOST: Double-dose vs Standard Dose Hepatitis B Vaccination in HIV-1-infected Patients
NCT00670839Phase 3Completed
- Sponsor
- ANRS
- Start
- May 2008
- Primary completion
- Dec 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of GenHevac-B in hepatitis B (HBV) (2 arms), sponsored by ANRS. Primary endpoint: Rate of HIV-infected patients who seroconvert at 28 weeks. Started May 2008; status: completed.
02
Drugs
GenHevac-B
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00670839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00670839.